Christopher Joyce Sells 10,611 Shares of Alignment Healthcare (NASDAQ:ALHC) Stock

Alignment Healthcare, Inc. (NASDAQ:ALHC) insider Christopher Joyce sold 10,611 shares of the firm’s stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $20.03, for a total transaction of $212,538.33. Following the completion of the transaction, the insider directly owned 297,088 shares of the company’s stock, valued at approximately $5,950,672.64. The trade was a 3.45% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Alignment Healthcare Price Performance

Shares of ALHC opened at $20.93 on Thursday. The company has a market cap of $4.19 billion, a P/E ratio of -174.42, a PEG ratio of 6.12 and a beta of 1.16. Alignment Healthcare, Inc. has a fifty-two week low of $11.48 and a fifty-two week high of $21.65. The company has a quick ratio of 1.61, a current ratio of 1.61 and a debt-to-equity ratio of 1.99. The firm’s 50 day moving average price is $18.55 and its 200 day moving average price is $16.46.

Alignment Healthcare (NASDAQ:ALHC) last posted its quarterly earnings results on Thursday, October 30th. The company reported $0.02 EPS for the quarter, topping the consensus estimate of ($0.01) by $0.03. Alignment Healthcare had a negative net margin of 0.57% and a negative return on equity of 16.23%. The business had revenue of $993.70 million during the quarter, compared to the consensus estimate of $980.90 million. During the same quarter in the previous year, the firm posted ($0.14) earnings per share. The company’s quarterly revenue was up 43.5% compared to the same quarter last year. On average, research analysts forecast that Alignment Healthcare, Inc. will post -0.69 earnings per share for the current fiscal year.

Alignment Healthcare News Roundup

Here are the key news stories impacting Alignment Healthcare this week:

• Positive Sentiment: Recent quarterly results showed revenue strength and an EPS beat (Qtr revenue ≈ $993.7M, +43.5% YoY; EPS $0.02 vs. consensus -$0.01), which supports growth expectations and helps explain upside interest from investors. Read More.
• Neutral Sentiment: Analyst coverage is active — some firms have raised price targets (consensus ~$21.25) while others remain neutral; Benzinga’s analyst roundup could amplify moves if any major upgrades or target changes are published. Read More.
• Negative Sentiment: Large insider sales were disclosed this week, including significant dispositions by President Dawn Maroney (100,000 shares sold ~Jan 2 and a separate filing showing 228,152 shares sold) and other executives (Christopher Joyce, Hyong Kim). Investors often interpret material executive selling near highs as profit-taking or reduced insider conviction, which can pressure the stock. Read More. • Read More.
• Negative Sentiment: A recent valuation-focused piece raises the question of whether current valuations already price in expected growth, signalling potential overpaying risk for new buyers if execution slows or multiples compress. That stokes caution even with solid top-line growth. Read More.

Hedge Funds Weigh In On Alignment Healthcare

A number of hedge funds and other institutional investors have recently bought and sold shares of ALHC. Larson Financial Group LLC acquired a new stake in shares of Alignment Healthcare in the 3rd quarter worth $33,000. SBI Securities Co. Ltd. raised its holdings in Alignment Healthcare by 4,868.9% during the second quarter. SBI Securities Co. Ltd. now owns 3,031 shares of the company’s stock worth $42,000 after purchasing an additional 2,970 shares in the last quarter. GAMMA Investing LLC lifted its position in Alignment Healthcare by 83.8% in the fourth quarter. GAMMA Investing LLC now owns 2,165 shares of the company’s stock valued at $43,000 after purchasing an additional 987 shares during the period. KBC Group NV acquired a new stake in Alignment Healthcare in the second quarter valued at about $44,000. Finally, Signaturefd LLC boosted its holdings in Alignment Healthcare by 142.6% in the 2nd quarter. Signaturefd LLC now owns 3,768 shares of the company’s stock valued at $53,000 after purchasing an additional 2,215 shares in the last quarter. 86.19% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

ALHC has been the topic of a number of analyst reports. UBS Group raised their price target on Alignment Healthcare from $17.00 to $18.00 and gave the company a “neutral” rating in a research note on Friday, October 31st. JPMorgan Chase & Co. increased their price objective on Alignment Healthcare from $20.00 to $23.00 and gave the company an “overweight” rating in a report on Wednesday, December 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alignment Healthcare in a report on Wednesday, October 8th. The Goldman Sachs Group reiterated a “buy” rating and set a $22.00 price target on shares of Alignment Healthcare in a research note on Monday, November 3rd. Finally, Barclays raised their price objective on shares of Alignment Healthcare from $13.00 to $18.00 and gave the stock an “equal weight” rating in a research report on Friday, October 31st. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Alignment Healthcare presently has an average rating of “Moderate Buy” and an average target price of $21.25.

About Alignment Healthcare

Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.

At the core of Alignment Healthcare’s approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.